Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sweden Leads In Linking Regulatory And Reimbursement Scientific Advice

Executive Summary

Sweden has been offering joint scientific advice to drug developers via a collaborative project between the country's reimbursement authority (TLV) and the Medical Products Agency (MPA).

You may also be interested in...



MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins

In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.

IQWiG’s First Cost-Effectiveness Review Could Take Drug HTA To New Frontiers

Germany’s reimbursement watchdog IQWiG’s first cost-effectiveness analysis uses four antidepressants as test case and finds they are overpriced.

NICE Scientific Advice Program May Seek Broader Application Through Boosting Regulator Link-Up

NICE’s scientific advice program, now in its third year, may need refocusing and increased co-operation with regulators to appeal to small and medium-sized companies.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel